<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>naltrexone Archives - Gateway Psychiatric</title>
	<atom:link href="https://www.gatewaypsychiatric.com/tag/naltrexone/feed/" rel="self" type="application/rss+xml" />
	<link></link>
	<description>Excellent Psychiatric Care</description>
	<lastBuildDate>Thu, 24 Jun 2021 13:20:38 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://i0.wp.com/www.gatewaypsychiatric.com/wp-content/uploads/2013/06/favicon2.png?fit=32%2C32&#038;ssl=1</url>
	<title>naltrexone Archives - Gateway Psychiatric</title>
	<link></link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">70562394</site>	<item>
		<title>Protected: Alcohol Use Disorder Guidelines</title>
		<link>https://www.gatewaypsychiatric.com/alcohol-use-disorder-guidelines/</link>
		
		<dc:creator><![CDATA[Peter Forster]]></dc:creator>
		<pubDate>Fri, 21 Apr 2017 17:03:30 +0000</pubDate>
				<category><![CDATA[Best Practices]]></category>
		<category><![CDATA[GPS]]></category>
		<category><![CDATA[Physical Conditions and Health]]></category>
		<category><![CDATA[Testing]]></category>
		<category><![CDATA[acamprosate]]></category>
		<category><![CDATA[alcohol abuse]]></category>
		<category><![CDATA[alcohol use]]></category>
		<category><![CDATA[blood phosphatidylethanol]]></category>
		<category><![CDATA[carbohydrate deficient transferrin]]></category>
		<category><![CDATA[cdt]]></category>
		<category><![CDATA[gabapentin]]></category>
		<category><![CDATA[gamma-glutamyl transferase]]></category>
		<category><![CDATA[ggt]]></category>
		<category><![CDATA[naltrexone]]></category>
		<category><![CDATA[ondansetron]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[topiramate]]></category>
		<guid isPermaLink="false">https://www.gatewaypsychiatric.com/?p=12934</guid>

					<description><![CDATA[<p>There is no excerpt because this is a protected post.</p>
<p>The post <a href="https://www.gatewaypsychiatric.com/alcohol-use-disorder-guidelines/">Protected: Alcohol Use Disorder Guidelines</a> appeared first on <a href="https://www.gatewaypsychiatric.com">Gateway Psychiatric</a>.</p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">12934</post-id>	</item>
		<item>
		<title>Naltrexone for Alcohol Use</title>
		<link>https://www.gatewaypsychiatric.com/naltrexone-alcohol-use/</link>
		
		<dc:creator><![CDATA[Peter Forster]]></dc:creator>
		<pubDate>Fri, 07 Oct 2016 19:36:12 +0000</pubDate>
				<category><![CDATA[Physical Conditions and Health]]></category>
		<category><![CDATA[alcohol abuse]]></category>
		<category><![CDATA[alcohol use]]></category>
		<category><![CDATA[carbohydrate craving]]></category>
		<category><![CDATA[craving]]></category>
		<category><![CDATA[naltrexone]]></category>
		<category><![CDATA[Vivitrol]]></category>
		<guid isPermaLink="false">https://www.gatewaypsychiatric.com/?p=11938</guid>

					<description><![CDATA[<p>Naltrexone is one of several new medications (the others are topirimate and acamprosate) that has been shown to reduce the risk of relapse in people with alcohol use disorders. But naltrexone is used relatively rarely for this purpose. A new study suggests that it may be possible to predict which patients are especially likely to respond to naltrexone treatment. The ... </p>
<div><a href="https://www.gatewaypsychiatric.com/naltrexone-alcohol-use/" class="more-link">Read More</a></div>
<p>The post <a href="https://www.gatewaypsychiatric.com/naltrexone-alcohol-use/">Naltrexone for Alcohol Use</a> appeared first on <a href="https://www.gatewaypsychiatric.com">Gateway Psychiatric</a>.</p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">11938</post-id>	</item>
		<item>
		<title>Weight Loss Medication</title>
		<link>https://www.gatewaypsychiatric.com/weight-loss-medication/</link>
		
		<dc:creator><![CDATA[Peter Forster]]></dc:creator>
		<pubDate>Sat, 04 Apr 2015 19:03:51 +0000</pubDate>
				<category><![CDATA[Physical Conditions and Health]]></category>
		<category><![CDATA[bupropion]]></category>
		<category><![CDATA[contrave]]></category>
		<category><![CDATA[medication]]></category>
		<category><![CDATA[naltrexone]]></category>
		<category><![CDATA[obesity]]></category>
		<category><![CDATA[side effects]]></category>
		<category><![CDATA[weight loss]]></category>
		<guid isPermaLink="false">https://www.gatewaypsychiatric.com/?p=8979</guid>

					<description><![CDATA[<p>A new pill with the brand name Contrave was recently approved for the treatment of obesity by the FDA. This pill is an extended release, fixed dose, combination of two previously approved medications: bupropion, a commonly used antidepressant which has also been approved as an aid to those were trying to stop smoking, and naltrexone, a medication that blocks the ... </p>
<div><a href="https://www.gatewaypsychiatric.com/weight-loss-medication/" class="more-link">Read More</a></div>
<p>The post <a href="https://www.gatewaypsychiatric.com/weight-loss-medication/">Weight Loss Medication</a> appeared first on <a href="https://www.gatewaypsychiatric.com">Gateway Psychiatric</a>.</p>
]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">8979</post-id>	</item>
	</channel>
</rss>
